Big data, real world, multi-state study finds RSV vaccine highly effective in protecting older adults against severe disease, hospitalization and death

This multi-state study is a real world data analyses of the effectiveness of the RSV -- short for respiratory syncytial virus -- vaccine. VISION Network researchers report that across the board these vaccines were highly effective in older adults, even those with immunocompromising conditions, during the 2023-24 respiratory disease season, the first season after RSV vaccine approval in the U.S.